Clinical Trial Update: Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] [Phase 2]

View source ↗

Summary

This is a phase 2 trial evaluating the Regorafenib plus Lorigerlimab RELO regimen in high-risk colorectal cancer with radiographic occult molecular residual dis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Lorigerlimab (lorigerlimab)
• Regorafenib (regorafenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colorectal Cancer, Regorafenib | Phase 2 | Status: SUSPENDED